Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Repaglinide

FDA-approved product (tablet, oral), marketed as Prandin, Repaglinide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Repaglinide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other blood glucose lowering drugs, excl. insulins
FDA pharmacologic class
Glinide FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Repaglinide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Repaglinide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetic Study to Characterize Individual Metabolic Profile

    NCT01188525 · start 2010-08

    Registered record
    Registry ID
    NCT01188525
    Conditions
    Healthy Volunteers
    Interventions
    10 parents drugs adminstration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    Intervention10 parents drugs adminstration
    PhasePhase 1
    Registry statusCompleted

  • An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients

    NCT01077570 · start 2010-03

    Registered record
    Registry ID
    NCT01077570
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-02
    Enrolment
    2,033

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide
    PhaseNot recorded
    Registry statusCompleted

  • Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

    NCT01022762 · start 2009-11

    Registered record
    Registry ID
    NCT01022762
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide; gliclazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-11
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide; gliclazide
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers

    NCT00959101 · start 2009-08

    Registered record
    Registry ID
    NCT00959101
    Conditions
    Diabetes; Healthy
    Interventions
    repaglinide and metformin combination tablet; repaglinide and metformin combination tablet; repaglinide; metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2009-10
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Healthy
    Interventionrepaglinide and metformin combination tablet; repaglinide and metformin combination tablet; repaglinide; metformin
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Latent Autoimmune Diabetes of the Adult

    NCT01140438 · start 2009-03

    Registered record
    Registry ID
    NCT01140438
    Conditions
    Diabetes
    Interventions
    metformin+ NPH insulin; metformin + sitagliptin +/- repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-03
    Completion
    2018-11
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    Interventionmetformin+ NPH insulin; metformin + sitagliptin +/- repaglinide
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs

    NCT00819741 · start 2009-02

    Registered record
    Registry ID
    NCT00819741
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide; metformin; repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-02
    Completion
    2009-11
    Enrolment
    433

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide; metformin; repaglinide
    PhasePhase 4
    Registry statusCompleted

  • Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions

    NCT00832481 · start 2009-01

    Registered record
    Registry ID
    NCT00832481
    Conditions
    Type 2 Diabetes
    Interventions
    Repaglinide; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-01
    Completion
    2009-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionRepaglinide; Metformin
    PhaseNot applicable
    Registry statusUnknown

  • Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide

    NCT00745433 · start 2008-01

    Registered record
    Registry ID
    NCT00745433
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide; metformin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-03
    Enrolment
    906

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide; metformin
    PhaseNot recorded
    Registry statusCompleted

  • Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes

    NCT00709917 · start 2007-03

    Registered record
    Registry ID
    NCT00709917
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-01
    Enrolment
    2,171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

    NCT00399711 · start 2006-11

    Registered record
    Registry ID
    NCT00399711
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide and metformin combination tablet; rosiglitazone and metformin combination tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2007-11
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide and metformin combination tablet; rosiglitazone and metformin combination tablet
    PhasePhase 3
    Registry statusCompleted

  • Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

    NCT00763412 · start 2006-11

    Registered record
    Registry ID
    NCT00763412
    Conditions
    Cystic Fibrosis Related Diabetes; Pancreatic Insufficiency
    Interventions
    placebo; repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-11
    Completion
    2013-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis Related Diabetes; Pancreatic Insufficiency
    Interventionplacebo; repaglinide
    PhaseNot applicable
    Registry statusCompleted

  • A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

    NCT00336310 · start 2006-07

    Registered record
    Registry ID
    NCT00336310
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2006-07
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionRepaglinide
    PhasePhase 4
    Registry statusUnknown

  • Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes

    NCT00231192 · start 2005-10

    Registered record
    Registry ID
    NCT00231192
    Conditions
    Diabetes
    Interventions
    Repaglinide and Insulin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2005-10
    Completion
    2007-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionRepaglinide and Insulin
    PhaseNot applicable
    Registry statusWithdrawn

  • Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

    NCT00568074 · start 2003-12-16

    Registered record
    Registry ID
    NCT00568074
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide; Glurenorm®; Glucobay®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-12-16
    Completion
    2004-09-02
    Enrolment
    131

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide; Glurenorm®; Glucobay®
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

    NCT00568984 · start 2002-11-21

    Registered record
    Registry ID
    NCT00568984
    Conditions
    Diabetes; Diabetes Mellitus, Type 2
    Interventions
    repaglinide; metformin; glicazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11-21
    Completion
    2003-11-10
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Diabetes Mellitus, Type 2
    Interventionrepaglinide; metformin; glicazide
    PhasePhase 4
    Registry statusCompleted